The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Recent updates from the MajesTEC-4 trial
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares some updates from the ongoing Phase III MajesTEC-4 trial (NCT05243797), which is comparing teclistamab in combination with lenalidomide versus lenalidomide alone or teclistamab alone as maintenance therapy in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
